A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Latest Information Update: 27 May 2025
At a glance
- Drugs KB 707 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Acronyms Opal 1
- Sponsors Krystal Biotech
Most Recent Events
- 30 Jan 2025 Planned number of patients changed from 140 to 240.
- 30 Jan 2025 Planned End Date changed from 1 Jul 2026 to 1 Jul 2027.
- 30 Jan 2025 Planned primary completion date changed from 1 Jul 2026 to 1 Jul 2027.